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Abstract
Perinatal hypoxic-ischemic encephalopathy (HIE), known as birth asphyxia, 
remains a major contributor to poor neurodevelopmental outcomes including 
cerebral palsy and seizures. One striking feature of HIE injury is a delayed pro-
gression of neuronal degeneration that spreads over time from the most severely 
damaged areas outward into neighboring undamaged regions. There is increasing 
evidence that these lesions act as sites of origin for waves of spreading depression 
(SD), a wave of neuronal and glial depolarization, that progressively enlarge 
the brain lesions. While the pathophysiology of SD is still under debate, there is 
increasing evidence that purinergic receptors in conjunction with connexin and 
pannexin 1 channels are necessary for sustained propagation of the waves and 
neuroinflammation. This review intends to discuss the relative contribution of 
purinergic signaling and connexin and pannexin 1 channels to trigger and spread 
SD waves leading to the development of progressive brain lesions under condi-
tions of perinatal HIE.
Keywords: spreading depression, gap junctions, hypoxic-ischemic encephalopathy, 
purinergic signaling
1. Introduction
Perinatal hypoxic-ischemic encephalopathy (HIE), also known as birth 
asphyxia, is a neurological syndrome that affects newborns worldwide, causing 
life lasting sequelae and not only impacting individual lives but also economy and 
public health systems [1, 2]. It is estimated that HIE occurs between 1 and 8 per 
1000 newborns, although this number can be widely more expressive accordingly 
to the region, especially in low-income countries [3, 4]. Besides, HIE is considered 
to be the third major cause of neonatal mortality, accountable for 23% of newborn 
deaths and averaging about 1 million children annually [5, 6]. In consonance, 
the morbidity is not far behind: HIE accounts for 10% of all cerebral palsy cases, 
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compromising the quality of life of these patients and their families [7–9]. In this 
scenario, understanding the factors and mechanisms involved in HIE etiology 
is crucial to the development of new therapeutic strategies and improvement of 
mortality and morbidity rates.
Over the last years, several studies emerged intending to explain the pathophysi-
ology of HIE [10–13]. The gaps in these topics are highlighted as particular priorities 
among the many critical areas that remain to be integrated. It is a consensus that the 
primary event for HIE burden is a global reduction of blood flow to the fetal brain 
during pregnancy or birth process [13]. This ischemic-hypoxic insult may result 
from various maternal or fetal conditions such as umbilical cord prolapse, rupture 
of the uterus and placental insufficiency [1, 14, 15]. One of the most intriguing fea-
tures of HIE, however, is not even the ischemic injury per se, but the ability of the 
initial lesion to expand to previously undamaged areas (i.e., secondary lesions) [16]. 
Much of this process remains undefined and saving perilesional regions at risk, 
termed penumbra, challenges physicians and scientists. In this context, increasing 
evidence supports extracellular ATP and purinergic receptors as significant players 
in HIE pathophysiology and, consequently, a unique addition as interventional tar-
gets for the limited repertoire of drugs currently available as therapeutic approaches 
for HIE [17–19].
Purinergic receptors are a class of ligand-gated receptors divided into two groups 
P1 and P2, responsive to nucleosides and nucleotides, respectively. P1 receptors 
have four members described (A1, A2A, A2B e A3) [20–22]. On the other hand, P2 
receptors are subdivided into two families P2Y and P2X. Both P2Y receptors and 
the P1 receptors are G coupled protein receptors (GPCRs), and the P2X receptors 
are ionotropic receptors. Those receptors are expressed in various systems in the 
organism, as the vascular system, the immune system, the gastrointestinal system, 
the renal system, and the central nervous system (CNS) [20–22]. Specifically, in 
the CNS, it is believed that some purinergic receptors could play essential roles in 
ischemia decreasing the symptoms and the extent of brain damage [23, 24].
Along with purinergic signaling, there are strong pieces of evidence in the 
literature correlating spreading depression (SD), a phenomenon characterized 
by self-sustained waves of depolarization of a sizeable population of cells, and 
hypoxic-ischemic insults [25, 26]. HIE-mediated SDs erupt in the brain, encumber-
ing tissue structure and function, and raising fascinating—and still unanswered—
questions concerning their initiation (i.e., genesis) and propagation. Even more 
ominously, erupting SDs accelerate tissue damage following HIE or traumatic brain 
injury (TBI) [27, 28]. Studies by many authors, including our group [29], suggest 
that lesions act as a site of origin to these waves, which slowly propagate through 
the brain surface [30]. So far, the role of glia (astrocytes and microglia) in initia-
tion, propagation, and recovery of SD is poorly understood [31, 32]. Although 
there is evidence that SD has an impact on astrocytes and microglia [31, 32], the 
consequences of their activation need to be further explored. Considering SD as 
an electrochemical event, ionic changes in the extracellular medium are important 
to the genesis and maintenance of propagated SDs. In this regard, recent studies 
present pannexins and connexins paved the way for sustainable SD propagation 
[26]. Hence, HIE detains a multifactorial mechanism, compelling not only puriner-
gic signaling but also spreading depression, connexins, pannexins and many other 
biological processes yet to be defined.
This article intends to review the aspects and empirical evidence made on HIE-
mediated brain injury through the functional interaction between purinergic signal-
ing, connexins, pannexins, and SDs. To the best of our knowledge, this is the first 
review to discuss the functional interplay among purinergic signaling and the above 
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mentioned “players” as key elements to trigger and to either support or to interrupt 
the propagation of waves of SD within the HIE’s penumbra. Understanding the 
underlying mechanisms of HIE is expected to develop more effective neuroprotec-
tive approaches during the highly prevalent condition of perinatal hypoxic distress.
2. Purinergic signaling
Since the first description of the physiological effects of purines and pyrimi-
dines, by Drury and Szent-Györgyi in 1929, several pieces of evidence increased 
the discussion on their activity in the context of the CNS [23, 24, 33–35]. This novel 
family of receptors is virtually expressed in all human cells types, including neurons 
and glial cells at central nervous system, hence raising the several hypotheses on 
their role in the context of a myriad of neurological disorders, such as, neurodegen-
erative diseases, traumatic brain injury, CNS tumors, epilepsy, psychiatric disor-
ders, and ischemic encephalopathy [36, 37].
The early 1970s classification of the novel receptor family—then called puri-
noreceptors—proposed by Geoffrey Burnstock is considered to be one of the first 
steps to current comprehension and systematic research of purinergic receptors, 
which stratifies them into two groups, taking in consideration their molecular 
characteristics and downstream signaling [38].
The adenosine-activated receptors, or P1 receptors, present four subtypes  
(A1, A2A, A2B, and A3), each of these consisting of seven folds of transmembrane 
protein domains (TM1-TM7) linked to an N-terminal extracellular domain and a 
C-terminal intracellular domain. In contrast, P2 receptors are subdivided into two 
families: metabotropic P2Y receptors and ionotropic P2X receptors. Among several 
other mammal species, humans present eight members of the metabotropic P2Y, 
(described as P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14), and seven 
members of the ionotropic P2X receptors, numbered P2X1 to P2X7 [22, 39–42].
The P1A2A and P1A2B molecules are Gs-protein-coupled receptors, therefore 
stimulating adenylate cyclase and leading to downstream production of cyclic 
adenosine 3′,5′-monophosphate (cAMP) second signaling, once they are bound 
to their active ligand. On the other, hand P1A1 and P1A3 subtypes molecules are 
Gi protein-coupled receptors, leading to adenylate cyclase inhibition and cAMP 
degradation. In addition, some of the A2B receptor isoforms may also be associated 
with Gq domains, leading to a phospholipase C and inositol triphosphate second 
signaling pathways [42] (Figure 1).
Metabotropic P2Y receptors are G protein-coupled receptors activated by 
different nucleotide types, including ATP, ADP, UTP, UDP, and UDP-glucose. 
Similarly to P1 receptors, the seven transmembrane domain/ns, three extracel-
lular and three intracellular loops, and C-terminal intracellular and extracellular 
N-terminal ends are found in their structure. P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 
receptors are associated with Gq protein, leading to an increase of the intracellular 
calcium through the internal stores culminating in a protein kinase C activation, 
whereas P2Y12, P2Y13, and P2Y14 are coupled to Gi protein, inhibiting adenyl-
ate cyclase and cyclic AMP [39]. Concerning the ionotropic P2X receptors, they 
are non-selective cation channels modulated by ATP [43]. Once activated these 
receptors act as transmembrane channels, allowing the flow of mono and divalent 
cations, such as, K+, Ca2+, and Na+ accordingly to their gradient [44, 45]. Although 
some data in this context is found to be controversial, it is important to mention 
that some subtypes as P2X2, P2X4, and P2X7 are described to open a non-selective 
transmembrane pore, if submitted to high concentrations or prolonged exposure 
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to their ligand. In this condition, these receptors allow the passage of molecules up 
to 900 Da, which includes organic ions and most of the frequently used fluorescent 
dyes [46–48] (Table 1). P2X receptors present two transmembrane domains con-
nected by an extracellular loop, besides a C-terminal and an N-terminal domain in 
the intracellular milieu [56]. They are capable of homotrimeric and heterotrimeric 
assemble [57, 58] (Figure 1).
As suggested before, the ischemic CNS context, purinergic receptors might 
represent an important molecular target to restrain the condition’s irreversible 
Figure 1. 
Structural features of Cx43, P2X7 and Panx1. Each functional P2X7 receptor is a trimer, with the three 
protein subunits arranged around a cation-permeable channel pore. The subunits all share a common topology, 
possessing two plasma membrane spanning domains (TM1 and TM2), a large extracellular loop with the ATP 
binding site, and containing 10 similarly spaced cysteines and glycosylation sites, and intracellular carboxyl (C) 
and amino termini (N). (Left) Connexin 43 (Cx43) and pannexin 1 (Panx1) (right) share similar membrane 
topology, with four α-helical transmembrane domains (M1–M4) connected by two extracellular loops and one 
cytoplasmic loop, where both amino NH2 (N) and carboxy COOH-termini (C) are intracellular. However, 
different from connexins, the pannexins possess an extracellular glycosylation site which impedes gap junction 
formation by these channels. Upper panel—(left) a Cx hemichannel (HC) and pannexon (right) are formed 
by connexins and pannexins, respectively, that oligomerize laterally.
Channel Blockers Dye Permeability
P2X7 BBG, oATP and AZ11645373 [49] Iodide propidium (+) –
A-438079, AZ11645373 and 
probenecid [50]
Ethidium bromide (+) and 
Lucifer yellow (−)
–
A-740003, PPADS and BBG [51] Yo-Pro-1 (+) –
Connexin 
Hemichannel
Heptanol, octanol, CBX, La3+, 
FFA and AGA [52]
Lucifer yellow (−) –
CBX and Gap26 [53] Ethidium bromide (+) –
CBX and mefloquine [54] Iodide propidium (+) –
CBX, FFA, AGA and NFA [55] Not used –
Pannexin 10Panx [50, 53] Ethidium bromide (+) No change
Nomenclature: –, decreased permeability/no permeability. BBG, brilliant blue G; oATP, periodate-oxidized 
adenosine triphosphate; CBX, carbenoxolone; AGA, 18alpha-glycyrrhetinic acid; FFA, flufenamic acid; PPADS, 
pyridoxalphosphate-6-azophenyl-2’,4’-disulfonic acid; NFA, niflumic acid. The (+) and (−) indicates valency of 
the dye used.
Table 1. 
P2X7, connexins and pannexins antagonists blocked the permeability to anionic and cationic dyes.
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burden. In this scenario, ATP and adenosine are released to the extracellular space 
after injury through vesicles from neurons, besides exocytosis and membrane 
channels including ABC transporters, pannexin 1, calcium homeostasis modulator 
1 (CALHM1) channels and P2X7 pore in glial cells [59]. Estimated extracellular ATP 
concentrations have been described to reach up to 700 nM after ischemic events 
leading to tissue necrosis, whereas adenosine levels can reach up to 1000 nM [17], 
due to ectonucleotidases’ activity, which catabolizes AMP and generates adenos-
ine consequently. These extracellular concentrations of adenosine and ATP after 
ischemic events are high enough to activate P1 and P2 receptors [60].
Even though purinergic receptors in the CNS are believed to play different roles 
during HIE, while the protective role of adenosine P1A1 receptors during ischemia 
is well accepted, through the reduction of infarct volume and improvement of 
neurological functions [61, 62], P2 receptors activation have been associated with 
inflammation, neurodegeneration and cell death [45, 63]. The evidence supporting 
an “adenosine neuroprotection” dates from 1997, when Halle and cols reported that 
pretreatment with 2-amino-3-benzothiophene (PD 81,273)—to increase adenosine 
binding to P1A1 receptors—conferred neuroprotection following HIE [24]. As 
expected, the neuroprotection afforded by adenosine is antagonized by theophyl-
line (dimethylxanthine), an inhibitor of phosphodiesterase (PDE) isoenzymes, 
which break down cyclic nucleotides in the cell and leads to increased concentra-
tions of [cAMP]i and [cyclic 3´,5´ guanosine monophosphate]I [64, 65], antagoniz-
ing P1A1 and P1A2 receptors at therapeutic concentrations [23]. Along the same 
line, Ådén et al. (2003) reported that the absence of P1A2A receptors (P1A2A KO 
mice) aggravated brain damage after neonatal HI [62].
All mammalian cell types express multiple P2 receptor subtypes, each of which 
presenting variable affinities for purine and pyrimidine nucleotides [66]. In the neona-
tal HI CNS, Wang et al. (2009) suggested that P2X7 downregulation in oligodendrocyte 
precursor cells confers neuroprotection [67], while the use of P2X7 antagonists, such 
as, A-438079 and JNJ-47965567, can antagonize the occurrence of seizures. In this 
context, P2X7 could represent a novel and effective therapeutic target in the condition 
mentioned above [68]. There is accumulating evidence that P2X1, P2X2, P2X3, P2X4 
and P2X5 are potentially involved in direct neuronal death [69, 70] and that P2X7 are 
expressed in glial cells [71]. It remains a matter of debate whether neurons express P2X7.
3. Connexins
Connexins are a family of trans-membrane proteins related to several functions, 
such as, intercellular communication and tissue differentiation. These proteins are 
best known for being the assembling subunits of connexons, a hexameric struc-
ture composed of six units of connexins [72–74]. The apposition of connexons in 
adjacent cells forms intercellular conduits named gap junctions (GJs), which allow 
the transfer of small molecules, ions and second messengers between cells [75]. 
The connexins family comprises 21 genes in the human genome [76], and their 
genetic expression varies according to the tissue and extracellular conditions. It 
is noteworthy that several cell types can express more than one type of connexin 
simultaneously [73, 77]. Connexins isoforms possess very similar and conserved 
structures, consisting of two extracellular loops, four transmembrane domains, one 
cytoplasmic loop, the C-terminus and the N-terminus [78]. When six units of iden-
tical connexins assemble, the resulting connexon is termed homomeric, whereas a 
connexon formed of different types of connexins is named heteromeric. Following 
the same rule, gap junctions are homotypic if derived from two identical connexons 
or heterotypic when two different connexons assemble [73] (Figure 1).
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Among all connexins isoforms, connexin 43 (Cx43) is the more widely 
expressed, being present in more than 30 different tissues [77]. Predominantly 
found in astrocyte’s membrane, novel studies suggest important participation of 
Cx43 connexons and GJs in the pathophysiology of several diseases [73, 79–82]. 
In the field of CNS hypoxic-ischemic insults, including neonatal asphyxia, some 
groups argue that GJs allows redistribution of nutrients, such as, glucose, and ATP 
[19], hence providing neuroprotection in this context. On the other hand, a myriad 
of studies presents Cx43 hemichannels as protagonists in processes of brain blood 
barrier disruption, calcium disbalance and mitochondrial dysfunction [83–85]. In 
addition, Cx43 may play an important role in the propagation of SD waves, possibly 
promoting the expansion of the initial injury to previously undamaged areas [26].
Under normal conditions, GJs may open or close accordingly to cell demands, 
while undocked connexons remain closed [86, 87]. Nevertheless, in cell death 
scenarios, hemichannels may open, allowing molecules to flow through the cell 
membrane, from and into the extracellular space [84, 88–90]. The release of sub-
stances, such as, ATP, glutamate and nicotinamide adenine dinucleotide (NAD+) 
in the extracellular medium promotes paracrine signaling to the surrounding cells, 
triggering cell death cascades and, consequently, expanding the primary injury [87].
Purinergic receptors in both neurons and glial cells can be activated from dying 
cell’s ATP release, leading to calcium influx through the receptor channel [83]. An 
increase of intracellular calcium might induce or worsen mitochondrial dysfunc-
tion in the context of brain injury, which leads to both secondary energy deficit 
and apoptosis [83]. In addition, ATP can also activate pattern recognition receptors 
(PRR), highlighting NOD-like receptor protein-3 (NLRP3) [84]. Finally, P2X7 and 
P2X4 receptors are involved in inflammasome activation and the secretion of pro-
inflammatory molecules.
One of the most widely characterized approach intending to prevent the inflam-
matory responses of purinergic receptors activation is Cx43 blockade. However, the 
effects of Cx43 blockade are still controversial. Several in vitro and in vivo models in 
the literature resulted in a reduction of cell death, tissue swelling, and lesion spread 
[91, 92]. In contrast, some groups described an association between Cx43 blockade, 
apoptosis and higher infarct volume [93, 94]. This divergence may be explained 
by the limited pharmacologic agents and approaches described to promote Cx43 
blockade. Currently, some of the most commonly used agents in the literature 
include Cx43 mimetic peptide, carbenoxolone, and octanol [19]. Once agents with 
greater specificity for Cx43 are established and their mechanisms are characterized, 
a better understanding of the role of Cx43 in pathological conditions such as HIE 
will be possible.
4. Pannexins
Pannexins are a class of monomeric proteins capable of forming cell membrane 
hemichannels, resembling structural and functional homology with the connexins 
as mentioned earlier. Likewise the formers, these molecules can assemble as oligo-
meric forms, namely pannexons. There are several different subtypes of pannexons 
in which pannexins can be assembled, depending on the cell type and physiologic 
condition of the cell surroundings. Among these, the three human isotypes are 
expressed virtually in all tissues: Panx1 (426 amino acids, 47.6 kDa), Panx2 (677 
amino acids, 74.4 kDa) and Panx3 (392 amino acids, 44.7 kDa) [84, 95, 96].
The characterization of the assembled pannexin polymers upon cell membrane 
is still controversial since several groups suggest their action to be in the hemichan-
nel fashion—such as connexins—while other findings indicate their function to 
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resemble full transmembrane channels between cells [84, 95, 96]. Despite the 
fact pannexins and connexins share several similar pharmacologic properties and 
expression patterns, unlike connexons, it is now believed that pannexons are not 
capable of forming functional gap junctions between neighbor cells and hence not 
being capable of promoting the connection between their cytoplasm [95, 97, 98].
Regarding molecular characterization, human pannexin isotypes share 50–60% 
of membrane sequence similarity, and their extracellular C-terminal sequences 
are the most variable among them, defining their subtype characterization based 
on their pattern of glycosylation [96, 98]. Novel structural studies of pannexin 
membrane characterization suggest that the physiologic interplay between Panx2 
and other subtypes, and functional gap junction formation are very unlikely in 
experimental scenarios due to glycosylated domain ionic repulsion [97, 98]. Panx2 
is believed to be exclusive to CNS cells, even though its molecular properties are not 
elucidated as well as Panx1 subtypes [95, 96] (Figure 1).
In contrast, Panx1 subtypes can be subdivided accordingly to their different 
expressed conformations, mostly determined by the several possible types of 
channel activation [97, 99]. Recent studies suggest that in the absence of specific 
ligands, Panx1 is a Cl-selective channel expressed in astrocytes, oligodendrocytes, 
and microglia [100]. In contrast, once activated by K+ ions, Panx1 can isomerize 
into a highly conductant non-selective channel (500 pS), permeable to molecules 
such as ATP and other nucleotide polymers. Alternatively, voltage-activation of 
Panx1 opens a lower conductance conformation (50 Ps) [97, 99]. Nonetheless, it is 
important to mention that caspase activity, mechanical stretching, osmotic changes, 
purinergic receptor activation (such as P2X7 bound to adenosine nucleotides), 
and other cell biomolecular survival pathways are indicated as panx1 activators 
[19, 43, 101]. Additionally, this suggests that tissue injury and cell death processes 
can mediate Panx1 activity and might explain one of the early mechanisms of ATP 
leakage through the cell membrane [97, 99] and intercellular activation through 
purinergic receptors, and coupling through functional gap junctions. The influence 
of extracellular ATP in astrocytes downstream signaling is further discussed in this 
review.
The evidence against the pannexin role as intercellular hemichannels is based on 
three major aspects of these protein characteristics. Firstly, their well-recognized 
function as ATP and other macromolecule releasers. In addition, their distribu-
tion is described mostly in the apical domains of ubiquitous cells, which makes 
hemichannel coupling very unlikely [95]. Lastly, the aforementioned glycosylated 
extracellular domain acts repealing the near plasmatic membrane and does not talk 
in favor of their gap junction formation [95–98].
Although it seems that hemichannel opening occurs only at the downhill of cell 
stress, Panx opening is also observed under physiological situations, such as, the 
glucocorticoid release throughout the circadian cycle and neuronal coordination 
under sleep pattern changing [102, 103]. Panx1 role was also described in inflam-
masome formation and the release and cleavage of IL-1β [101, 104], which might 
suggest a role in the triggering of early inflammatory response and cell death [105].
5. Spreading depression
In 1906, Sir William Gowers described migraine pathophysiology as an intense, 
yet slow activity of the cortical centers of the brain spreading as “ripples in a pond 
into which a stone is thrown”—“occupying 20 min or so in passing through center 
affected” leaving a state of “molecular disturbance of the structures” [106]. This 
phenomenon was confirmed and described 38 years later in rabbit’s cerebral cortexes 
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by Aristides Leão, who coined the term spreading depression (SD) [107], nowadays 
associated not only with migraine pathophysiology but also with several other neu-
rological disorders, such as, traumatic brain injury, spinal cord injury, subarachnoid 
and intracranial hemorrhage, stroke and HIE [28, 108–111] (Figure 2).
Characterized as an intense change in ionic homeostasis and extracellular space 
(ECS) features, SD is an all-direction depression of neural activity that does not 
respect any tissue cellularity boundaries in the cortex [30, 112]. Although it is 
described as a negative shift in DC moving a few millimeters per minute, SD also 
involves fast electrical events, as seen in a burst of activity at the wavefront, fol-
lowed closely by the numbness of preview neuronal tissue [27, 28, 30, 113, 114]. SD 
used to be described by Professor Hiss Martins-Ferreira as an “electrical tsunami” 
spreading among a neuronal mass that encompasses dendritic swelling, gap junc-
tion channels assemble and opening, mitochondrial changes, up-regulation, and 
down-regulation of several other proteins of the CNS [26, 115, 116].
Figure 2. 
Waves of Leão spreading depression (SD) and purinergic receptors. Three-step models have been proposed to 
explain genesis and propagation of SDs, a phenomenon believed to play a major role in the pathophysiology 
of HIE. Firstly, HIE-mediated primary injury leads to a surge in [K+]o, ATP, reactive oxygen species (ROS) 
and a number of neurotransmitters (NT) in the extracellular space through Cx hemichannels and Panx1 
opening in dying cells (gray cell). The upcoming activation of purinergic receptors at glia [71] and/or at 
neighboring neuron cell surfaces (blue cells)—a matter of debate (?)—triggering SD phenomenon. Besides, 
glutamate excitotoxicity is also triggered, leading to Ca2+ influx in the adjacent cells through NMDA receptors. 
Transmembrane ionic shifts during SD leads to a large drop in [Na+]o, [Ca2+]o, [Cl−]o, simultaneously 
with the extracellular DC potential shift. Subsequently (third step), reentrant waves spread throughout the 
penumbra mediated by gap junctions, promoting secondary damage—via apoptosis—and lesion enlargement 
[30]. Electrotonic junctions in the neonatal cerebral cortex (see inset—bottom) are mostly dendrodendritic—
although these same neurons can also be interconnected by chemical synapses [38]—and are believed to provide 
an important path for propagation of the waves [42]). Microglia (pink cell) is also activated via P2X4 and 
P2X7 receptors and releases proinflammatory cytokines.
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Among this complex electrochemical phenomenon that revolves in the CNS 
extracellular space, the intracellular spaces of neuronal-glial populations, and cel-
lular coupling, many factors have been attributed as key players to its genesis and 
sustenance, such as, Ca2+, K+, and glutamate and purinergic receptors [30]. Highly 
increased K+ concentration was demonstrated in SD scenarios, which lead to sev-
eral experimental models intending to recapitulate SD waves through artificially 
increasing this ionic concentration on the cortical surface [29]. It was also observed 
that the levels of this ion in the ECS reaches typically a plateau, being trespassed 
once SD is elicited [117] and those higher amounts of K+ deliverance increase 
wave frequencies. Moreover, the fast electrical burst at SD wavefront is possibly 
explained by high extracellular K+ concentrations inducing high neuronal activity. 
Imaging studies assessing initial changes in Ca2+, glutamate, and K+ concentrations 
at SD wavefront revealed earlier and more significant changes in K+, suggesting its 
role as the first responder in SD initiation and propagation [118] (Figure 2).
Astrocytic Ca2+ waves are also intrinsically related to SD, sharing its “velocity of 
propagation and stimulation paradigms” initiation stimuli, refractory period, and 
signaling characteristics, which are postulated not only as involved with the initia-
tion of SD, but also as fundamental for its propagation [30, 119–121]. However, 
Ca2+ waves are not a sine qua non player for SD genesis, as observed in a Ca2+ free 
medium, in ion chelating experimental contexts, in which SD genesis was not inhib-
ited, albeit it caused a lower onset and faster recovery [119] (for further evidence 
against this Ca2+ role, see [122–124]). It is noteworthy that, gap junction blockers, 
purinergic blockers, ATP hydrolase inducers, and desensitization of the purinergic 
receptors were reported as potential Ca2+ wave inhibitors [30, 125–128].
The myriad of aforementioned cationic changes in SD scenarios implies in 
several anionics unbalances in the ECS, being Cl− the most affected inorganic anion 
[30]. Consequently, Na+ follows the elicited Cl− influx, decreasing ECS tonicity 
leading to cell swelling and morphologic changes in dendritic spines [129]. The 
dendritic spines recovery depends on mitochondrial membrane potential integrity, 
an already impaired function in hypoxic-ischemic scenarios [130].
Glutamate concentration is not only found to be higher during and after SD but 
also its release to be synchronic and excitotoxic processes are triggered by NMDAr 
activation. Despite these events, the blockade of this neurotransmitter is not able to 
inhibit SD onset [131–133].
The roles of purinergic signaling in neurodegeneration following perinatal HIE 
contexts is also well documented. Levels of extracellular ATP in the brain increase 
during ischemia, activating both P1 and P2 receptors expressed on neural cells 
(neuronal and glial). Hence, extracellular ATP levels are postulated to be involved 
in the pathophysiology of post-ischemic inflammation and extent of brain injury 
[17, 45, 81, 83, 134]. Despite this factor is being considered to be one of the key play-
ers in triggering SD through Panx1 and Cx hemichannels in dying cells, the propa-
gation of the waves requires the participation of gap junctional channels within 
the ischemic penumbra [19, 30, 115, 135]. Therefore, the hypothesis of a functional 
interplay between P2X7, Panx1, and Cx, and its impact in the injury enlargement is 
very plausible in the context of the HI newborn cerebral cortex development  
[19, 104, 130, 136]. In consonance with this conclusion, the blockade of genesis and 
propagation of SD through purinergic antagonists and GJ blockers may represent 
a viable therapeutic approach, not only to prevent post-HIE neonatal brain injury 
expansion, but also in other neurovascular disorders, including migraine, trauma, 
and ischemic stroke [19] (Figure 2).
Mitochondrial activity is fundamental to cell maintenance, carrying in itself 
an intricate and distinct pattern of protein, ionic and electrical activity [137–139]. 
Both oxygen and glucose deprivations unbalance the primary source of cellular 
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ATP production through the disruption of mitochondrial oxidative phosphoryla-
tion chain [140–143]. This described powerhouse organelle failure generates a toxic 
[Ca2+]i increase, caspase activation, and ROS production, which induces necrotic 
features of the HIE-mediated primary injury [142, 143]. We are lead to believe that 
this characteristic of cell membrane rupture is the main contributing path for Cx 
hemichannel opening; acting synergically with the Panx1 heightening of ATP and 
K+ in ECS. Henceforth, we postulate this described cascade of hemichannel events 
to be the first step for SD genesis and propagation in HIE [95, 99, 136, 144]. The 
opening of these pores induces several other cell-signaling events, such as P2X7 
activation and glutamate excitotoxic activity that is leading to significant Ca2+ 
concentration increase in the ECS. Ionic shifts and DC change is followed by gap 
junction-mediated spiral waves, promoting secondary SD-mediated injury [29] 
(Figure 2).
In conclusion, Cx hemichannels opening may elicit Ca2+ waves—responsible for 
the faster onset of SD-ATP, caspases, NO and other second signaling molecules flow, 
contributing to the bystander cell killing effect among coupled astroglial cells [145]. 
This highway-rail for SD waves intensifies its onset, as longs as [Ca2+]i augmentation 
is followed by Cl−, Na+ influx, leading to ECS changes (“Chemical Tsunami”) [30]. 
Depolarizing wavefront will also elicit neuronal bursts, contributing to K+ and ATP 
increase in the biophase [146]. The cited secondary injury appears to behave in a 
positive feedback-like fashion, into which further ionic and ATP release will lead to 
SD frequency increase and the ECS changes to mechanical panx1 activation.
6. Biomarkers
Inflammation plays a critical role in HIE [147, 148] by the complex inter-
play between neutrophils, lymphocytes, adhesion molecules, cytokines, and 
chemokines, causing injury in neurons, glial cells, and white matter. The 
blood-brain barrier is disrupted leading to egress of brain chemicals, normally 
only found in the CNS, and circulate peripherally. These chemicals can serve as 
important biomarkers that may help in disease risk stratification and clinical 
decision-making.
Hypoxia-ischemia induces activation of microglia and astrocytes [149, 150], 
resulting in secretion of inflammatory cytokines and chemokines that influence 
neuronal viability and recovery [149]. Following brain injury, purinergic P2 recep-
tors and extracellular ATP play an important role in the microglial inflammatory 
response [151]. While P2 receptors are activated during oxygen-glucose deprivation 
(OGD) leading to microglia activation with cytokine release [70, 152] and subse-
quent neuronal death, the enhanced expression of P2X4 mediates ATP induced 
amoeboid microglial cell activation for production of proinflammatory cytokines 
[153] in postnatal hypoxic rats. In particular, P2X7 expression is increased 24 h after 
neonatal hypoxia-induced seizures in mouse pups following global hypoxia and 
injection of P2X7 antagonist reduced the frequency of electrographic seizures and 
EEG abnormality [68]. Therefore, purinergic biomarkers have been proposed for 
both cerebral ischemia diagnosis and prognosis [45].
Microglia responds vigorously to hypoxic-ischemic attack and produce excess 
inflammatory cytokines [148]. Newborns with HIE have higher levels of interleu-
kins IL-1, IL-6, IL-8, IL-10, tumor necrosis factor TNF-α, transforming growth fac-
tor TGF-β and monocyte chemoattractant protein MCP-1 that correlate positively 
with brain injury severity [154–157]. IL-1β plays an important role in brain injury 
during ischemia [158]. The mechanism of brain damage induced by IL-1β involves 
the release of free radicals, enhancing the toxicity of excitatory amino acids and 
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increasing vascular permeability resulting in secondary cerebral edema. Blood and 
cerebrospinal fluid (CSF) IL-1β, IL-6, and TNF-α concentrations were found higher 
in HIE neonates compared to control group and a high CSF/serum ratio suggested 
cytokine production in the brain in addition to the systemic cytokines crossing the 
blood-brain barrier [154, 159]. Therapeutic hypothermia (TH), a well established 
treatment for neonates with HIE [8, 10, 157, 159, 160], has been shown to perform 
a role in the prevention of inflammatory process by maintaining proinflammatory 
IL-6 at low levels and anti-inflammatory IL-10 at high levels [160] (Figure 2).
7. Discussion
HIE remains one of the leading causes of neonatal deaths [5, 6]. Although mul-
tiple factors have been implicated in this disorder, the HIE underlying mechanisms 
are yet to be elucidated. To the best of our knowledge, we provide herein a sum-
mary of the described functional interplay among purinergic signaling, pannexins, 
connexins, and SD waves in HIE pathophysiology. Based on this interaction, the 
present work intends to review the current information on potential biomarkers on 
HIE diagnosis and prognosis.
SD waves spread across the cortex at rates of 2–5 mm/min [30, 107, 161], accom-
panied by a slow negative extracellular voltage and ions movement depolarizing 
neurons and astrocytes followed by a period of electrical suppression of distinct 
neuronal populations. The propagation of the SD waves is more significant in fields 
enriched with dendrodendritic synapses [162], such as, those described in the 
inner plexiform layer of the retina [30]. At this time, there are no comprehensive 
reviews of SD, from genesis to sustained propagation for which gap junctions have 
been reported to be essential [30]. However, the fact that the temporal and spatial 
characteristics of intercellular Ca2+ waves in astrocytes are remarkably similar to 
those of SDs “contributed, in part, to the mischaracterization of this phenomena”  
[30, 113]. Even though both events fail when gap junctions are blocked, the latest 
(i.e., Ca2+ waves) is neither antagonized by glutamate receptor blockers nor by 
purinergic receptor antagonists [30] (Tables 1 and 2).
Considering the role of spreading depression waves in HIE etiology, a new panel 
of biomarkers are being proposed to improve accuracy in diagnosis and prognosis, 
especially in the disease earlier stages or milder presentations. Unfortunately, ATP 
and adenosine, with short half-lives, do not offer good performance as biomark-
ers [174]. Recent studies have supported the use of proton magnetic resonance 
spectroscopy (MRS), a quantitative, noninvasive method of detecting energy 
metabolism disturbances in the neonate’s brain as a marker in outcome prediction 
for HIE patients [175]. In these studies, it seems that the ratios including Lactate/N-
acetylaspartate and N-acetylaspartate/creatine could be a potential prognostic 
biomarker to evaluate neurodevelopmental outcomes [176, 177]. However, larger 
prospective multicenter studies with a standardized protocol for both measurement 
protocols and analysis methods are required to validate such protocols.
As discussed, cytokines are key players in the inflammatory mechanism, 
contribute to the progression of ischemic damage and are released by SD-activated 
glia. Waves of SD cause a considerable perturbation of the ionic environment in 
the brain, which are readily detected by microglia—although the role of microg-
lial activation in SD-related neurological disorders remains a matter of debate. 
There is increasing evidence that supports that glia (astrocytes, oligodendrocytes 
and microglia) may play a key role in triggering SD waves. It is known that CNS 
microglia become activated due to the increase in extracellular ATP from the depo-
larization of neurons and glia, by propagated waves of SD and from the release 
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Channel Model Blocker(s) Effects
P2X7 In vivo MCAO (rat) RB2 (10–100 mg/kg) RB2 improved neurological 
score and reduced brain-
damaged area [163]
In vivo 4-VO (rat) BBG and oATP (1, 5 and 
10 μg) and A-438079 (0.03, 
0.3 and 3 μg)
P2X7 antagonists increased 
neuronal survival and 
improved behavioral deficits. 
They reduced mortality, glial 
activation, and cytokine 
transcription [164].
In vivo 4-VO (rat) BBG (50 mg/kg) and 
A-740003 (0.04 mm/kg)
P2X7 antagonist, BBG, 
reduced cell death, microglial 
microvesicle-like components, 
expression of IL-1β, p-38 
phosphorylation and glial 
activation. BBG and A-740003 
improved memory functions 
[165]
In vivo carotid arteries 
occlusion and post-
conditioning (mouse)
BBG (20–40 mg/kg) BBG abolished neuroprotective 
effects produced by post-
conditioning, such as memory, 
and motor performance 
improvement [166]
P2Y Culture of rat primary 
cortical neurons subjected 
to OGD
N/A Ischemic tolerance [167]
Culture of astrocytes 
exposed to sublethal OGD 
and subsequent lethal OGD
N/A Ischemic tolerance [168]
Connexin Perinatal ischemia-
intrauterine hypoxia-
ischemia (rat)
Carbenoxolone (105 mg/kg) Decreased neuronal death, 
apoptosis, histopathologic 
damage and developmental 
impact. Decreased clustering of 
dying cells [169]
Perinatal ischemia-bilateral 
carotid ligation (sheep)
Cx43 mimetic peptide 
(50 μmol/kg)
Reduced seizure activity and 
status epilepticus. Improved 
neuronal and oligodendrocytes 
survival [170]
Neonate 7D hypoxia/
ischemia-carotid ligation 
and hypoxic chamber (rat)
Cx43 mimetic peptide 
(25–50 μg/kg)
Reduced infarct volume, 
astrogliosis, glutamate release 
and improved neurological 
function [171]
Pannexin In vivo 4-VO (rat) Probenecid (2 mg/kg) Probenecid attenuated 
neuronal death, cathepsin B 
translocation in neurons and 
glial reactivity [172]
In vivo MCAO (Mouse) Probenecid (1 mg/ml) Probenecid reduced infarct 
size, neurological deficit, 
brain water content, astrocytic 
activation and inhibited 
HMGB1 and AQP4 expression 
[173]
MCAO, middle cerebral arterial occlusion; 4-VO, four-vessel occlusion; RB2, reactive blue 2; BBG, brilliant blue G; 
oATP, periodate-oxidized adenosine triphosphate; OGD, oxygen-glucose deprivation; N/A: not applied.
Table 2. 
Key findings of P2X7, P2Y, connexins and pannexins blockade in brain ischemia models.
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of chemicals through damaged plasma membranes of dying cells [178]. Activated 
microglia secrete pro-inflammatory mediators such as cytokines and develop 
phagocytic and major histocompatibility complex (MHC) class II-restricted 
antigen presenting characteristics. Although microglia express almost all P2X 
members (P2X1, P2X4, P2X5, and P2X7), these receptors are expressed in different 
levels and contribute distinctly to neuroinflammation [148]. One of the central 
cytokines produced by these cells is IL-1β, which plays essential roles in brain 
injury during ischemia, such as, IL-6 secretion [89, 179]. In bone marrow-derived 
macrophages, P2X7 activation plays a significant role in the release of IL-1β [180]. 
In microglia, however, evidence suggests that other receptors, highlighting P2X4, 
may be protagonists along with P2X7 in IL-1β release [180]. Hence, despite the fact 
that purinergic biomarkers are not available, cytokines induced by P2X activa-
tion are measurable in serum and might be useful as diagnostic and prognostic 
indicators.
Although TH is a current standard therapy for neonatal HIE [8, 10, 157, 159, 160], 
no serum biomarker is in current clinical use for this high-risk population. Using 
a serum panel of biomarkers rather than a single biomarker and combining them 
with acid-base values, Apgar score, clinical signs of encephalopathy, early EEG 
and MRI could help in identifying the infants with the highest risk of compromise. 
None of the proposed biomarkers, so far, has yet been established as clearly better 
than clinical evaluation of HIE for recruitment of infants at risk of adverse out-
comes. Also, even though some of the putative biomarkers show good correlations 
with outcome, they do so only after the onset of the subsequent deterioration (e.g., 
12 or 24 h or even later). In practice, this means that the search continues for a panel 
of biomarkers with high diagnostic and prognostic accuracy that can be identified 
early in the disease process to aid the bedside clinician in tailoring treatment to 
individual HIE newborns.
List of abbreviations
4-VO four-vessel occlusion
AGA 18alpha-glycyrrhetinic acid
BBG brilliant blue G
CALHM1 calcium homeostasis modulator 1
cAMP cyclic adenosine monophosphate
CBX carbenoxolone
CNS central nervous system
CSF cerebrospinal fluid
Cx connexin
ECS extracellular space
FFA flufenamic acid
GJ gap junction
GPCRs G coupled protein receptors
HI hypoxic-ischemia
HIE hypoxic-ischemic encephalopathy
MCAO middle cerebral arterial occlusion
MCP-1 monocyte chemoattractant protein-1
MHC major histocompatibility complex
MRS proton magnetic resonance spectroscopy
NFA niflumic acid
oATP periodate-oxidized adenosine triphosphate
OGD oxygen-glucose deprivation
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Panx pannexin
PDE phosphodiesterase
PPADS pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid
RB2 reactive blue 2
ROS reactive oxygen species
SD spreading depression
TBI traumatic brain injury
TH therapeutic hypothermia
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